ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0314

Lack of Systemic Effects from Intra-articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2 Trial

Leonard Kapural1, Stephen D. Collins2, Eric Grigsby3, Mark McBride4, Jayson Rieger5, Morgan Stokes6, Howard Rutman6 and Flavia Cicuttini7, 1Center for Clinical Research, Winston-Salem, NC, 2Xalud Therapeutics, Inc., Chicago, IL, 3Neurovations Clinical Research, Napa, CA, 4Instat Clinical Research, Chatham, NJ, 5PBM Capital, Charlottesville, VA, 6Xalud Therapeutics, Inc., Berkeley, CA, 7Monash University, Melbourne, Australia

Meeting: ACR Convergence 2023

Keywords: clinical trial, gene therapy, Interleukins, Osteoarthritis, pain

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0308–0324) Osteoarthritis – Clinical Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: This study (NCT04124042) was designed to assess the safety, tolerability, and efficacy of XT-150, a non-viral gene therapy, in adult participants with moderate to severe pain due to osteoarthritis (OA) of the knee. XT-150 is a plasmid designed to locally express a proprietary version of the anti-inflammatory cytokine, interleukin (IL)-10. IL-10 has been shown to play a key role in pain reversal but has proven a challenging therapeutic candidate due to its short half-life.1 We hypothesize that local expression of IL-10 via gene therapy may be a more appropriate route of administration for sustained effects and has shown acceptable safety profiles and no-anti-IL-10 antibodies in previous clinical and pre-clinical studies.2

Methods: We describe safety results from a two-stage double-blind Phase 2 study. Stage A compared 2 active doses of XT-150 to a placebo (phosphate-buffered saline) control arm. Stage B was a 6-month follow-up with the option to randomly receive a single injection of XT-150 at one of two doses (0.15 or 0.45 mg) between Day 180 and Day 330. All intra-articular (IA) injections of XT-150 or placebo were performed under imaging guidance (Table 1). Participants 45-85 years of age had symptomatic knee OA defined as a WOMAC Pain score of ≥8 (out of 20) and Kellgren-Lawrence grade 2 or 3 at screening. After signing the Informed Consent Form (ICF), all were assessed for safety by physical examination, laboratory assessments, vital signs, adverse events (AEs) and serious AEs (SAEs) throughout the study. All participants (N=286) receiving any amount of XT-150 or placebo were included in the safety analysis. Safety data were summarized using descriptive statistics according to a prespecified statistical analysis plan (SAP).

Results: Drug-related AEs in this study were local with no systemic AEs. Local injection drug-related treatment-emergent adverse events (TEAEs) were reported by 6 patients (2%); arthralgia was the most common (Table 2). Overall, XT-150 was generally well tolerated in single and multiple IA injections. No dose-, treatment-, or sequence-related trends were reported for any safety domain for XT-150 (Table 3). The most commonly occurring TEAE for all participants who received active study drug was arthralgia (13% of participants). One unrelated TEAE of Grade 5 intensity, a myocardial infarction, was reported following the second dose in a patient with a history of CVD. SAEs were reported across all arms and treatment sequences with a total of 17 (6%) participants reporting 18 SAEs over the 360-day study period, all of which were considered unrelated to the study treatment. There were no AEs of special interest related to study treatment. Anti-IL-10 antibodies were not detected after single or repeat injections.

Conclusion: Safety data from this study support continued investigation of XT-150 for the management of pain and improvement of physical function in patients with knee OA. The local nature of treatment-related AEs and the absence of treatment-related SAEs support a two-dose regimen of 0.45 mg XT-150 (total dose of 0.9 mg) as safe and well-tolerated for future studies.

1. Kwilasz AJ, et al. Neuropharmacology. 2015;96(Pt A):55-69; 2. Watkins LR, et al. Brain Behav Immun. 2020 Nov;90:155-166.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: L. Kapural: Avanos, 1, 5, Gimer, 1, Nalu, 5, Neuralace, 5, Neuros, 1, Nevro, 1, 5, PainTeq, 1, Presidio, 1, Saluda, 5; S. Collins: Xalud Therapeutics, Inc., 1, 4, 8, 11; E. Grigsby: Eli Lilly, 5, Jointstem, 5, Kolon Tissuegene, 5, Medtronic, 2, 5, Neuros, 5, Sollis Therapeutics, 2, Tenex Health Inc., 2, Xalud Therapeutics, 2; M. McBride: None; J. Rieger: Xalud Therapeutics, 4, 8, 10; M. Stokes: Xalud Therapeutics, 3; H. Rutman: Xalud Therapeutics, 3, 11; F. Cicuttini: Xalud Therapeutics, Inc., 5.

To cite this abstract in AMA style:

Kapural L, Collins S, Grigsby E, McBride M, Rieger J, Stokes M, Rutman H, Cicuttini F. Lack of Systemic Effects from Intra-articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2 Trial [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/lack-of-systemic-effects-from-intra-articular-xt-150-for-the-treatment-of-moderate-to-severe-pain-due-to-oa-of-the-knee-safety-results-from-a-phase-2-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lack-of-systemic-effects-from-intra-articular-xt-150-for-the-treatment-of-moderate-to-severe-pain-due-to-oa-of-the-knee-safety-results-from-a-phase-2-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology